Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accounts Payables: 2011-2025

Historic Accounts Payables for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $24.0 million.

  • Adma Biologics' Accounts Payables rose 49.94% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 49.94%. This contributed to the annual value of $20.2 million for FY2024, which is 29.11% up from last year.
  • Per Adma Biologics' latest filing, its Accounts Payables stood at $24.0 million for Q3 2025, which was down 19.31% from $29.8 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Accounts Payables peaked at $29.8 million during Q2 2025, and registered a low of $6.2 million during Q2 2021.
  • Over the past 3 years, Adma Biologics' median Accounts Payables value was $16.0 million (recorded in 2024), while the average stood at $17.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 116.58% in 2021, then slumped by 56.93% in 2023.
  • Quarterly analysis of 5 years shows Adma Biologics' Accounts Payables stood at $12.4 million in 2021, then grew by 6.43% to $13.2 million in 2022, then increased by 18.38% to $15.7 million in 2023, then rose by 29.11% to $20.2 million in 2024, then skyrocketed by 49.94% to $24.0 million in 2025.
  • Its last three reported values are $24.0 million in Q3 2025, $29.8 million for Q2 2025, and $20.6 million during Q1 2025.